1,759 results on '"Green, Michael R."'
Search Results
2. Loss of TDP-43 function contributes to genomic instability in amyotrophic lateral sclerosis
3. Contributors
4. Best practices for the ATAC-seq assay and its data analysis
5. Rewiring cancer drivers to activate apoptosis
6. Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma
7. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma
8. Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer
9. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions
10. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis
11. Advancing CAR T cell therapy through the use of multidimensional omics data
12. HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B
13. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease
14. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
15. Author Correction: Rewiring cancer drivers to activate apoptosis
16. EZH2 inhibits NK cell–mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner
17. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma
18. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2
19. Identification of Rocaglate Acyl Sulfamides as Selective Inhibitors of Glioblastoma Stem Cells.
20. Pharmacological reactivation of inactive X-linked Mecp2 in cerebral cortical neurons of living mice.
21. Inhibition of MALT1 and BCL2 induces synergistic anti-tumor activity in models of B cell lymphoma
22. Abstract P11: ARID1A mutations shape memory B-cell dynamics and confer sensitivity to SWI/SNF remodeling complex inhibition in lymphoma
23. EZH2 inhibition reactivates epigenetically silenced FMR1 and normalizes molecular and electrophysiological abnormalities in fragile X syndrome neurons
24. Genomic Drivers in Follicular Lymphoma
25. KLF7 promotes pancreatic cancer growth and metastasis by up-regulating ISG expression and maintaining Golgi complex integrity
26. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma
27. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens
28. Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death
29. Harnessing lymphoma epigenetics to improve therapies
30. ESRRB regulates glucocorticoid gene expression in mice and patients with acute lymphoblastic leukemia
31. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study
32. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma
33. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
34. Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells
35. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway
36. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy
37. A KLF4-DYRK2–mediated pathway regulating self-renewal in CML stem cells
38. The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing
39. TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein
40. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1
41. A ticking clock for B cell tumors
42. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells
43. Genetic and pharmacological reactivation of the mammalian inactive X chromosome
44. Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A
45. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
46. EZH2 inhibition reactivates epigenetically silenced FMR1 and normalizes molecular and electrophysiological abnormalities in fragile X syndrome neurons.
47. Borrowing Transcriptional Kinases to Activate Apoptosis
48. Loss of TDP-43 function contributes to genomic instability in amyotrophic lateral sclerosis
49. CREBBP lysine acetyltransferase domain mutations create zombie enzymes that alter chromatin loading dynamics and prevent EP300 redundancy
50. CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.